Skip to main content

Table 2 Risk of local failure, regional failure, distant failure, recurrence, and death according to levels of inflammatory blood markers

From: Different inflammatory blood markers correlate with specific outcomes in incident HPV-negative head and neck squamous cell carcinoma: a retrospective cohort study

  Pts Local failure Regional failure Distant failure Recurrence/Death Death
  HR (95% CI)a Wald \(\chi\)2 HR (95% CI)a Wald \(\chi\)2 HR (95% CI)a Wald \(\chi\)2 HR (95% CI) Wald \(\chi\)2 HR (95% CI) Wald \(\chi\)2
Neutrophil-to-lymphocyte ratio (NLR)
 < 2.10 311 Ref   Ref   Ref   Ref   Ref  
2.10 to < 3.76 406 0.97 (0.64–1.47) p = 0.8815 1.76 (1.12–2.75) p = 0.0139 1.14 (0.71–1.86) p = 0.5813 1.05 (0.83–1.34) p = 0.6739 1.05 (0.81–1.36) p = 0.7063
 ≥ 3.76 208 1.15 (0.71–1.87) p = 0.5733 1.82 (1.06–3.14) p = 0.0303 1.37 (0.78–2.40) p = 0.2710 1.47 (1.12–1.92) p = 0.0048 1.39 (1.05–1.85) p = 0.0231
Platelet-to-lymphocyte ratio (PLR)
 < 127.7 465 Ref   Ref   Ref   Ref   Ref  
127.7 to < 162.8 228 0.87 (0.56–1.34) p = 0.5267 1.52 (0.95–2.44) p = 0.0808 0.83 (0.48–1.44) p = 0.5089 1.15 (0.90–1.45) p = 0.2629 1.17 (0.91–1.51) p = 0.2251
 ≥ 162.8 232 1.44 (0.97–2.13) p = 0.0718 1.98 (1.24–3.15) p = 0.0043 1.67 (1.08–2.58) p = 0.0208 1.35 (1.07–1.71) p = 0.0111 1.30 (1.01–1.68) p = 0.0413
Lymphocyte-to-monocyte ratio (LMR)b
 ≥ 4.28 188 Ref   Ref   Ref   Ref   Ref  
2.92 to < 4.28 331 1.57 (0.87–2.86) p = 0.1363 1.55 (0.86–2.81) p = 0.1488 1.17 (0.62–2.19) p = 0.6348 1.24 (0.92–1.68) p = 0.1643 1.20 (0.87–1.67) p = 0.2667
 < 2.92 405 2.16 (1.22–3.84) p = 0.0087 1.89 (1.10–3.25) p = 0.0220 1.44 (0.79–2.65) p = 0.2348 1.58 (1.18–2.12) p = 0.0021 1.52 (1.11–2.09) p = 0.0098
Systemic inflammatory marker (SIM)b
 < 1.40 423 Ref   Ref   Ref   Ref   Ref  
1.40 to < 2.46 295 1.00 (0.65–1.56) p = 0.9861 1.32 (0.86–2.01) p = 0.2046 1.60 (1.02–2.50) p = 0.0400 1.14 (0.90–1.44) p = 0.2727 1.20 (0.94–1.54) p = 0.1463
 ≥ 2.46 206 1.42 (0.90–2.23) p = 0.1277 1.57 (0.97–2.52) p = 0.0655 1.26 (0.72–2.21) p = 0.4160 1.48 (1.15–1.91) p = 0.0024 1.43 (1.09–1.89) p = 0.0099
Systemic immune-inflammation index (SII)
 < 602 501 Ref   Ref   Ref   Ref   Ref  
602 to < 754 127 0.83 (0.49–1.42) p = 0.5027 1.24 (0.72–2.14) p = 0.4404 1.01 (0.55–1.86) p = 0.9706 0.98 (0.74–1.31) p = 0.8913 0.97 (0.71–1.32) p = 0.8480
 ≥ 754 297 1.23 (0.85–1.79) p = 0.2786 1.66 (1.10–2.51) p = 0.0157 1.33 (0.87–2.02) p = 0.1887 1.37 (1.11–1.70) p = 0.0034 1.32 (1.05–1.66) p = 0.0171
  1. Hazard ratio (HR) and corresponding 95% confidence interval (CI) were estimated through Cox proportional hazard model, adjusting for study centre, gender, age, cancer site, pT, pN, surgical margins, extranodal extension, and adjuvant (chemo) radiotherapy. Optimal biomarkers’ cut-offs were determined through iterative procedure which maximize predictability on overall survival
  2. aAdjusted for competing risk according to Fine and Gray model. bOne patients has missing data